Las Vegas, NV -- (SBWIRE) -- 12/24/2013 -- EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more. EquityObserver.com issues a special report on the following stocks: Synergy Pharmaceuticals Inc(NASDAQ:SGYP),Solta Medical Inc(NASDAQ:SLTM),Generex Biotechnology Corporation(OTCMKTS:GNBT), ZIOPHARM Oncology Inc.(NASDAQ:ZIOP)
Synergy Pharmaceuticals Inc(NASDAQ:SGYP)managed to keep its gain at 8.56% on above-normal volume of 1.63Mshares. The stock settled at $4.69, after floating in a range of $4.44 - 4.73. Its latest price has reached market capitalization of $422.95M. Its 52-week range has been $3.83 - 7.44. Synergy Pharmaceuticals, Inc. is a biopharmaceutical company focused primarily on the development of drugs to treat gastrointestinal (GI), disorders and diseases.
How Should Investors Trade SGYP Now?Don’t Miss out a Special Trend Analysis
Solta Medical Inc(NASDAQ:SLTM)trading on a volume of 2.16Mshares, higher than its standard daily volume. Shares have been closed at $2.97. Over the last twelve months, the stock has gained13.36% and faced a worst price of $1.44.Solta Medical, Inc. designs, develops, manufactures and markets professional and consumer energy-based medical device systems for aesthetic applications.
Is SLTM a Solid Investment at These Levels?Read This Report for Details
Generex Biotechnology Corporation(OTCMKTS:GNBT)is down at $0.0295 on above- normal volume of 1.94Mshares during the last trading day. The stock has its 12-month range $0.02 - 0.07. Its Intraday range is $0.03 - 0.03.Generex Biotechnology Corporation is a Canada-based Company, which develops drug delivery systems and technologies for the treatment of diabetes.
How Should Investors Trade GNBT Now?Don’t Miss out a Special Trend Analysis
In the last trading day, ZIOPHARM Oncology Inc.(NASDAQ:ZIOP)is on high volume, trading at a volume of versus its average daily volume ratio 1.59M/1.19M shares. At $4.27, the stock has attained market capitalization of 418.38M.ZIOPHARM Oncology, Inc., is a biotechnology company. The Company employs gene expression and control technology to deliver deoxyribonucleic acid (DNA) for the treatment of cancer.
Will Investors Buy ZIOP After Reading This News?Just Go Here and Find Out
About Equity Observer
Equity Observer delivers intra-day insights into the equities, tech and investment world. The website is a window into what’s going on in the business world and why.
EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more.
The disclaimer is to be read and fully understood before using our site, or joining our email list.
http://www.equityobserver.com/ has a no tolerance spam policy; we will not sell or re-distribute your email to any 3rd party. A If applicable, please also unsubscribe from the newsletter using the link at the bottom of the email if you no longer wish to receive our emails. We only send our newsletters to opt-in members.
PLEASE NOTE WELL: The http://www.equityobserver.com/ employees and contributors are NOT registered as an Investment Adviser in any jurisdiction whatsoever.
Read Full Disclaimer at: http://www.equityobserver.com/disclaimer-2/
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)